Thaler Roman, Maurizi Antonio, Roschger Paul, Sturmlechner Ines, Khani Farzaneh, Spitzer Silvia, Rumpler Monika, Zwerina Jochen, Karlic Heidrun, Dudakovic Amel, Klaushofer Klaus, Teti Anna, Rucci Nadia, Varga Franz, van Wijnen Andre J
From the Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of Social Health Insurance Vienna (WGKK) and Austrian Social Insurance for Occupational Risks (AUVA) Trauma Center Meidling, First Medical Department, Hanusch Hospital, 1140 Vienna, Austria, Department of Orthopedic Surgery and Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota 55905, and.
Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
J Biol Chem. 2016 Mar 25;291(13):6754-71. doi: 10.1074/jbc.M115.678235. Epub 2016 Jan 12.
Bone degenerative pathologies like osteoporosis may be initiated by age-related shifts in anabolic and catabolic responses that control bone homeostasis. Here we show that sulforaphane (SFN), a naturally occurring isothiocyanate, promotes osteoblast differentiation by epigenetic mechanisms. SFN enhances active DNA demethylation viaTet1andTet2and promotes preosteoblast differentiation by enhancing extracellular matrix mineralization and the expression of osteoblastic markers (Runx2,Col1a1,Bglap2,Sp7,Atf4, andAlpl). SFN decreases the expression of the osteoclast activator receptor activator of nuclear factor-κB ligand (RANKL) in osteocytes and mouse calvarial explants and preferentially induces apoptosis in preosteoclastic cells via up-regulation of theTet1/Fas/Caspase 8 and Caspase 3/7 pathway. These mechanistic effects correlate with higher bone volume (∼20%) in both normal and ovariectomized mice treated with SFN for 5 weeks compared with untreated mice as determined by microcomputed tomography. This effect is due to a higher trabecular number in these mice. Importantly, no shifts in mineral density distribution are observed upon SFN treatment as measured by quantitative backscattered electron imaging. Our data indicate that the food-derived compound SFN epigenetically stimulates osteoblast activity and diminishes osteoclast bone resorption, shifting the balance of bone homeostasis and favoring bone acquisition and/or mitigation of bone resorptionin vivo Thus, SFN is a member of a new class of epigenetic compounds that could be considered for novel strategies to counteract osteoporosis.
像骨质疏松症这样的骨退行性病变可能由控制骨稳态的合成代谢和分解代谢反应中与年龄相关的变化引发。在此我们表明,萝卜硫素(SFN),一种天然存在的异硫氰酸盐,通过表观遗传机制促进成骨细胞分化。SFN通过Tet1和Tet2增强活性DNA去甲基化,并通过增强细胞外基质矿化和成骨细胞标志物(Runx2、Col1a1、Bglap2、Sp7、Atf4和Alpl)的表达促进前成骨细胞分化。SFN降低骨细胞和小鼠颅骨外植体中破骨细胞激活剂核因子-κB配体(RANKL)的表达,并通过上调Tet1/Fas/半胱天冬酶8和半胱天冬酶3/7途径优先诱导前破骨细胞凋亡。与未处理的小鼠相比,用SFN处理5周的正常小鼠和去卵巢小鼠的这些机制效应与更高的骨体积(约20%)相关,这是通过微型计算机断层扫描确定的。这种效应是由于这些小鼠中更高的小梁数量。重要的是,通过定量背散射电子成像测量,在SFN处理后未观察到矿物质密度分布的变化。我们的数据表明,这种源自食物的化合物SFN通过表观遗传刺激成骨细胞活性并减少破骨细胞的骨吸收,改变骨稳态的平衡,有利于体内骨量增加和/或减轻骨吸收。因此,SFN是一类新的表观遗传化合物的成员,可考虑将其用于对抗骨质疏松症的新策略。